Ankündigung • Jan 03
Avid Bioservices, Inc. to Delist from Public Exchanges UK-based private equity firm GHO Capital Partners LLP and its US peer Ampersand Capital Partners have obtained a US anti-trust approval for their USD 1.1 billion (EUR 1.06 billion) deal to buy biologics contract development manufacturing organisation (CDMO) Avid Bioservices, Inc. (NASDAQ:CDMOP). The transaction will see Avid delisted from public exchanges. The firm will continue to operate under its current name. Recent Insider Transactions Derivative • Dec 29
President notifies of intention to sell stock Nicholas Green intends to sell 146k shares in the next 90 days after lodging an Intent To Sell Form on the 26th of December. If the sale is conducted around the recent share price of US$12.22, it would amount to US$1.8m. For the year to April 2021, Nicholas' total compensation was 15% salary and 85% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since December 2023, Nicholas' direct individual holding has decreased from 169.61k shares to 0. Company insiders have collectively sold US$3.3m more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions • Dec 27
President recently sold US$2.8m worth of stock On the 24th of December, Nicholas Green sold around 227k shares on-market at roughly US$12.29 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Nicholas has been a net seller over the last 12 months, reducing personal holdings by US$2.9m. Major Estimate Revision • Dec 17
Consensus revenue estimates increase by 16% The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from US$140.0m to US$162.2m. EPS estimate unchanged from -US$0.31 at last update. Biotechs industry in the US expected to see average net income decline 12% next year. Consensus price target of US$12.88 unchanged from last update. Share price was steady at US$12.36 over the past week. Reported Earnings • Dec 11
Second quarter 2025 earnings: EPS and revenues miss analyst expectations Second quarter 2025 results: US$0.27 loss per share (further deteriorated from US$0.15 loss in 2Q 2024). Revenue: US$33.5m (up 32% from 2Q 2024). Net loss: US$17.4m (loss widened 83% from 2Q 2024). Revenue missed analyst estimates by 3.5%. Earnings per share (EPS) also missed analyst estimates by 130%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 84 percentage points per year, which is a significant difference in performance. Ankündigung • Nov 15
Punch and Associates Sends Letter to Board of Directors of Avid Bioservices, Inc On November 14, 2024, Punch & Associates Investment Management, Inc. announced its intention to vote AGAINST the proposed acquisition of Avid Bioservices, Inc. by GHO Capital and Ampersand Capital. Punch & Associates believes the $12.50 per share offer materially undervalues Avid and is opportunistically timed to capitalize on low valuations, ignoring key assets such as idle production capacity, medium-term earnings potential, and net operating losses. Punch & Associates emphasized that if the bid is not significantly raised to reflect the true value of the company, it is willing to remain a public shareholder. Punch & Associates criticized the Board's recommendation of a sale at a minimal premium, especially as Avid’s financial performance improves following years of challenges, including a significant capacity expansion, industry downturn, and balance sheet mismanagement. Punch & Associates called the proposal illogical and reiterated its plan to vote against it. Ankündigung • Nov 08
Funds managed by GHO Capital Partners LLP and Ampersand Management LLC entered into a definitive merger agreement to acquire Avid Bioservices, Inc. (NasdaqCM:CDMO) for approximately $850 million. Funds managed by GHO Capital Partners LLP and Ampersand Management LLC entered into a definitive merger agreement to acquire Avid Bioservices, Inc. (NasdaqCM:CDMO) for approximately $850 million on November 6, 2024. Under the terms of the merger agreement, GHO and Ampersand would acquire all the outstanding shares held by Avid’s stockholders for $12.5 per share in cash, for a transaction valued at approximately $1.1 billion. Upon completion of the transaction, Avid common stock will no longer be listed on any public stock exchange. The Company will continue to operate under the Avid name and brand. Sell side termination fee is $32 million and buy side termination fee is $64 million. The transaction is subject to subject to customary closing conditions, including expiration or termination of any waiting periods applicable to the consummation of the Merger under the Hart-Scott-Rodino Antitrust Improvements Act, approval by Avid’s stockholders and receipt of required regulatory approvals. The deal has been unanimously approved by the the Avid Board of Directors. The expected completion of the transaction is first quarter of 2025. Moelis & Company LLC acted as financial advisor and William B. Sorabella of Cooley LLP acted as legal advisor for Avid Bioservices, Inc. Neill P. Jakobe, Timothy A. Castelli and Zachary R. Blume of Ropes & Gray LLP acted as legal advisor for Ampersand Management LLC and GHO Capital Partners LLP. William Blair acted as financial advisor to Ampersand Management LLC and GHO Capital Partners LLP. Recent Insider Transactions Derivative • Oct 15
President exercised options and sold US$173k worth of stock On the 10th of October, Nicholas Green exercised options to acquire 17k shares at no cost and sold these for an average price of US$10.05 per share. This trade did not impact their existing holding. For the year to April 2021, Nicholas' total compensation was 15% salary and 85% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since December 2023, Nicholas' direct individual holding has increased from 169.61k shares to 226.65k. Company insiders have collectively sold US$133k more than they bought, via options and on-market transactions in the last 12 months. Major Estimate Revision • Sep 16
Consensus EPS estimates fall by 29% The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -US$0.227 to -US$0.292 per share. Revenue forecast unchanged at US$163.7m. Biotechs industry in the US expected to see average net income decline 14% next year. Consensus price target up from US$12.50 to US$13.50. Share price rose 25% to US$11.16 over the past week. Ankündigung • Sep 11
Avid Bioservices, Inc. Reiterates Earnings Guidance for the Fiscal Year 2025 Avid Bioservices, Inc. reiterated earnings guidance for the fiscal year 2025. For the year, the company maintains Revenue Guidance of Between $160 Million and $168 Million. Price Target Changed • Sep 10
Price target increased by 14% to US$14.00 Up from US$12.25, the current price target is an average from 4 analysts. New target price is 56% above last closing price of US$8.95. Stock is down 13% over the past year. The company is forecast to post a net loss per share of US$0.27 next year compared to a net loss per share of US$2.23 last year. Reported Earnings • Sep 10
First quarter 2025 earnings: EPS and revenues miss analyst expectations First quarter 2025 results: US$0.087 loss per share (further deteriorated from US$0.034 loss in 1Q 2024). Revenue: US$40.2m (up 6.5% from 1Q 2024). Net loss: US$5.53m (loss widened 161% from 1Q 2024). Revenue missed analyst estimates by 1.6%. Earnings per share (EPS) also missed analyst estimates by 64%. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 66 percentage points per year, which is a significant difference in performance. Ankündigung • Sep 04
Avid Bioservices, Inc. to Report Q1, 2025 Results on Sep 09, 2024 Avid Bioservices, Inc. announced that they will report Q1, 2025 results After-Market on Sep 09, 2024 Ankündigung • Aug 29
Avid Bioservices, Inc., Annual General Meeting, Oct 16, 2024 Avid Bioservices, Inc., Annual General Meeting, Oct 16, 2024. Major Estimate Revision • Jul 09
Consensus EPS estimates fall by 21% The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -US$0.187 to -US$0.227 per share. Revenue forecast unchanged at US$162.8m. Biotechs industry in the US expected to see average net income decline 10% next year. Consensus price target of US$12.50 unchanged from last update. Share price was steady at US$7.17 over the past week. Reported Earnings • Jul 05
Full year 2024 earnings: EPS misses analyst expectations Full year 2024 results: US$2.23 loss per share (down from US$0.004 profit in FY 2023). Revenue: US$139.9m (down 6.3% from FY 2023). Net loss: US$140.8m (down US$141.0m from profit in FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates significantly. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has only fallen by 34% per year, which means it has not declined as severely as earnings. Ankündigung • Jul 03
Avid Bioservices Provides Earnings Guidance for Fiscal Year 2025 Avid Bioservices provided earnings guidance for fiscal Year 2025. For the period, the company expects revenue of $160 million to $168 million. Ankündigung • Jul 02
Avid Bioservices, Inc. to Report Fiscal Year 2024 Final Results on Jul 02, 2024 Avid Bioservices, Inc. announced that they will report fiscal year 2024 final results After-Market on Jul 02, 2024 Board Change • Jun 12
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Independent Director Esther Alegria was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Ankündigung • Mar 21
Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q Avid Bioservices, Inc. announced it received a notice (the “Notice”) on March 19, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) advising the company that it was not in compliance with Nasdaq’s continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the “Rule”) as a result of its failure to file its Quarterly Report on Form 10-Q for the fiscal quarter ended January 31, 2024 (the “Form 10-Q”) in a timely manner. The Rule requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission (the “SEC”). The company previously reported in its Form 12b-25 filed with the SEC on March 12, 2024 that the company was unable to file the Form 10-Q within the prescribed time period due to the need to restate and file certain prior period financial statements as a result of the continued classification of the company’s 1.250% Exchangeable Senior Notes due 2026 as long-term liabilities following an event of default, as more fully described in the company’s Current Report on Form 8-K filed with the SEC on March 12, 2024. Under Nasdaq rules, the company has 60 calendar days from the receipt of the Notice, or until May 20, 2024, to submit a plan to regain compliance with the Rule. If Nasdaq accepts the company’s plan, Nasdaq may grant the company up to 180 calendar days from the due date of the Form 10-Q (as extended by Rule 12b-25 of the Securities Exchange Act of 1934, as amended), or until September 16, 2024, to regain compliance. The company intends to file the Form 10-Q as promptly as reasonably practicable. If the company does not file the Form 10-Q by May 20, 2024, the company intends to timely submit a plan to regain compliance with the Rule. Ankündigung • Mar 08
Avid Bioservices, Inc. announced that it expects to receive $160 million in funding Avid Bioservices, Inc announced a private placement of Convertible Senior Unsecured Notes due 2029 for a gross proceeds of $160 million on March 6, 2024. The notes are offered to qualified institutional buyers. The company expects to price the Offering before open of market on March 7, 2024. The 2029 Notes will represent senior unsecured obligations of the company and will accrue interest payable semiannually in arrears. Upon conversion, the company will pay or deliver, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at its election. The interest rate, initial conversion rate and other terms of the notes will be determined at the time of pricing of the Offering. Ankündigung • Mar 07
Avid Bioservices, Inc. Maintains Revenue Guidance for Full Fiscal Year 2024 Avid Bioservices, Inc. announced that the company is maintaining revenue guidance for full fiscal year 2024 of $137 million to $147 million. Board Change • Jan 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Independent Director Esther Alegria was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Recent Insider Transactions • Dec 19
Director recently bought US$135k worth of stock On the 15th of December, Richard Hancock bought around 23k shares on-market at roughly US$5.86 per share. This transaction amounted to 41% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth US$191k. Despite this recent purchase, insiders have collectively sold US$86k more in shares than they bought in the last 12 months. Major Estimate Revision • Dec 14
Consensus EPS estimates fall by 121% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from US$154.1m to US$138.9m. Losses expected to increase from US$0.12 per share to US$0.26. Biotechs industry in the US expected to see average net income growth of 8.2% next year. Consensus price target down from US$18.50 to US$13.00. Share price rose 2.7% to US$5.34 over the past week. Reported Earnings • Dec 08
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Second quarter 2024 results: US$0.15 loss per share (further deteriorated from US$0.019 loss in 2Q 2023). Revenue: US$25.4m (down 27% from 2Q 2023). Net loss: US$9.51m (loss widened US$8.35m from 2Q 2023). Revenue missed analyst estimates by 24%. Earnings per share (EPS) also missed analyst estimates by 140%. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings. Ankündigung • Dec 08
Avid Bioservices, Inc. Revises Revenue Guidance for the Full Fiscal Year 2024 Avid Bioservices, Inc. revised revenue guidance for the full fiscal year 2024. The company is adjusting revenue guidance for full fiscal year 2024 to $137 million to $147 million, previously $145 million and $165 million. Ankündigung • Dec 01
Avid Bioservices, Inc. to Report Q2, 2024 Results on Dec 07, 2023 Avid Bioservices, Inc. announced that they will report Q2, 2024 results After-Market on Dec 07, 2023 Buying Opportunity • Oct 28
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 53%. The fair value is estimated to be US$7.78, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 7.1% in a year. Earnings is forecast to decline by 46% in the next year. Recent Insider Transactions • Sep 24
Independent Chairman recently bought US$191k worth of stock On the 21st of September, Joseph Carleone bought around 20k shares on-market at roughly US$9.53 per share. This transaction amounted to 27% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Joseph's only on-market trade for the last 12 months. Major Estimate Revision • Sep 14
Consensus EPS estimates fall by 139% The consensus outlook for fiscal year 2024 has been updated. 2024 expected loss increased from -US$0.045 to -US$0.107 per share. Revenue forecast unchanged at US$155.2m. Biotechs industry in the US expected to see average net income decline 3.0% next year. Consensus price target down from US$19.75 to US$19.25. Share price fell 16% to US$10.31 over the past week. Price Target Changed • Sep 08
Price target decreased by 7.2% to US$19.25 Down from US$20.75, the current price target is an average from 4 analysts. New target price is 78% above last closing price of US$10.83. Stock is down 41% over the past year. The company is forecast to post a net loss per share of US$0.11 compared to earnings per share of US$0.009 last year. Ankündigung • Sep 08
Avid Bioservices, Inc. Reiterates Revenue Guidance for Full Fiscal Year 2024 Avid Bioservices, Inc. reiterated revenue guidance for full fiscal year 2024. For the period, the company expects revenue to be between $145 million and $165 million. Ankündigung • Sep 01
Avid Bioservices, Inc. to Report Q1, 2024 Results on Sep 07, 2023 Avid Bioservices, Inc. announced that they will report Q1, 2024 results After-Market on Sep 07, 2023 Ankündigung • Aug 29
Avid Bioservices, Inc., Annual General Meeting, Oct 23, 2023 Avid Bioservices, Inc., Annual General Meeting, Oct 23, 2023, at 10:00 Pacific Standard Time. Agenda: To elect seven directors to serve on Board of Directors until our 2024 annual meeting of stockholders, with each director to hold office until his or her successor is duly elected and qualified or until his or her earlier death, resignation or removal; to ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending April 30, 2024; to approve, by an advisory vote, a non-binding resolution approving the compensation of the Company’s named executive officers; to approve, by an advisory vote, the frequency of holding future advisory votes on the compensation of our named executive officers; and to conduct any other business properly brought before the 2023 annual meeting and any adjournment or postponement there of. Recent Insider Transactions Derivative • Aug 02
President exercised options and sold US$254k worth of stock On the 31st of July, Nicholas Green exercised options to acquire 20k shares at no cost and sold these for an average price of US$12.99 per share. This trade did not impact their existing holding. For the year to April 2021, Nicholas' total compensation was 10% salary and 90% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since September 2022, Nicholas' direct individual holding has increased from 69.71k shares to 127.86k. Company insiders have collectively sold US$2.9m more than they bought, via options and on-market transactions in the last 12 months. Price Target Changed • Jul 26
Price target decreased by 11% to US$19.75 Down from US$22.25, the current price target is an average from 4 analysts. New target price is 53% above last closing price of US$12.92. Stock is down 34% over the past year. The company is forecast to post a net loss per share of US$0.028 compared to earnings per share of US$0.009 last year. Recent Insider Transactions Derivative • Jul 02
President exercised options and sold US$519k worth of stock On the 29th of June, Nicholas Green exercised options to acquire 41k shares at no cost and sold these for an average price of US$12.70 per share. This trade did not impact their existing holding. For the year to April 2021, Nicholas' total compensation was 10% salary and 90% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since September 2022, Nicholas' direct individual holding has increased from 69.71k shares to 83.53k. Company insiders have collectively sold US$3.4m more than they bought, via options and on-market transactions in the last 12 months. Major Estimate Revision • Jun 28
Consensus revenue estimates fall by 14% The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from US$181.3m to US$156.7m. Forecast loss of -US$0.027, down from profit of US$0.12 per share profit previously. Biotechs industry in the US expected to see average net income decline 85% next year. Consensus price target down from US$22.25 to US$20.75. Share price fell 18% to US$13.13 over the past week. New Risk • Jun 23
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 0.4% Last year net profit margin: 107% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.4x net interest cover). High level of non-cash earnings (38% accrual ratio). Minor Risks Profit margins are more than 30% lower than last year (0.4% net profit margin). Significant insider selling over the past 3 months (US$288k sold). Reported Earnings • Jun 23
Full year 2023 earnings: EPS misses analyst expectations Full year 2023 results: EPS: US$0.009 (down from US$2.08 in FY 2022). Revenue: US$149.3m (up 25% from FY 2022). Net income: US$560.0k (down 100% from FY 2022). Profit margin: 0.4% (down from 107% in FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 25%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 96% per year but the company’s share price has only increased by 32% per year, which means it is significantly lagging earnings growth. Ankündigung • Jun 15
Avid Bioservices, Inc. to Report Q4, 2023 Results on Jun 21, 2023 Avid Bioservices, Inc. announced that they will report Q4, 2023 results After-Market on Jun 21, 2023 Valuation Update With 7 Day Price Move • May 18
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to US$15.21, the stock trades at a forward P/E ratio of 163x. Average forward P/E is 10x in the Biotechs industry in the US. Total returns to shareholders of 175% over the past three years. Recent Insider Transactions Derivative • May 04
Insider notifies of intention to sell stock Mark Ziebell intends to sell 32k shares in the next 90 days after lodging an Intent To Sell Form on the 1st of May. If the sale is conducted around the recent share price of US$18.05, it would amount to US$581k. Since June 2022, Mark's direct individual holding has increased from 14.98k shares to 40.12k. Company insiders have collectively sold US$2.7m more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions • Apr 13
Independent Director recently sold US$142k worth of stock On the 11th of April, Gregory Sargen sold around 7k shares on-market at roughly US$20.24 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$229k more than they bought in the last 12 months. Recent Insider Transactions Derivative • Apr 06
Director exercised options and sold US$69k worth of stock On the 3rd of April, Richard Hancock exercised 5k options at a strike price of around US$4.67 and sold these shares for an average price of US$18.46 per share. This trade did not impact their existing holding. Since June 2022, Richard's direct individual holding has increased from 35.20k shares to 39.13k. Company insiders have collectively sold US$2.0m more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions Derivative • Mar 19
Chief Financial Officer notifies of intention to sell stock Daniel Hart intends to sell 5k shares in the next 90 days after lodging an Intent To Sell Form on the 14th of March. If the sale is conducted around the recent share price of US$18.79, it would amount to US$94k. Since June 2022, Daniel's direct individual holding has increased from 29.22k shares to 49.96k. Company insiders have collectively sold US$2.1m more than they bought, via options and on-market transactions in the last 12 months. Reported Earnings • Mar 14
Third quarter 2023 earnings released Third quarter 2023 results: Net income: (down US$2.25m from profit in 3Q 2022). Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 123% per year but the company’s share price has only increased by 66% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Mar 10
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to US$13.95, the stock trades at a forward P/E ratio of 440x. Average forward P/E is 10x in the Biotechs industry in the US. Total returns to shareholders of 252% over the past three years. Major Estimate Revision • Mar 09
Consensus EPS estimates fall by 217% The consensus outlook for fiscal year 2023 has been updated. 2023 expected loss increased from -US$0.015 to -US$0.047 per share. Revenue forecast of US$146.6m unchanged since last update. Biotechs industry in the US expected to see average net income decline 42% next year. Consensus price target of US$22.33 unchanged from last update. Share price fell 5.6% to US$15.47 over the past week. Recent Insider Transactions Derivative • Mar 05
Director exercised options and sold US$60k worth of stock On the 1st of March, Richard Hancock exercised 5k options at a strike price of around US$4.67 and sold these shares for an average price of US$16.59 per share. This trade did not impact their existing holding. Since June 2022, Richard's direct individual holding has increased from 35.20k shares to 39.13k. Company insiders have collectively sold US$2.1m more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions Derivative • Feb 05
Director exercised options and sold US$57k worth of stock On the 1st of February, Richard Hancock exercised 5k options at a strike price of around US$4.67 and sold these shares for an average price of US$16.02 per share. This trade did not impact their existing holding. Since March 2022, Richard's direct individual holding has increased from 35.20k shares to 39.13k. Company insiders have collectively sold US$2.2m more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions • Jan 18
Independent Director recently sold US$87k worth of stock On the 13th of January, Esther Alegria sold around 5k shares on-market at roughly US$16.32 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Recent Insider Transactions Derivative • Jan 13
President exercised options and sold US$117k worth of stock On the 10th of January, Nicholas Green exercised options to acquire 8k shares at no cost and sold these for an average price of US$14.44 per share. This trade did not impact their existing holding. For the year to April 2021, Nicholas' total compensation was 10% salary and 90% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since June 2022, Nicholas' direct individual holding has increased from 28.55k shares to 77.43k. Company insiders have collectively sold US$2.1m more than they bought, via options and on-market transactions in the last 12 months. Major Estimate Revision • Dec 13
Consensus forecasts updated The consensus outlook for 2023 has been updated. 2023 revenue forecast increased from US$143.8m to US$146.3m. Now expected to report loss of -US$0.01 instead of US$0.07 per share profit. Biotechs industry in the US expected to see average net income decline 93% next year. Consensus price target down from US$26.00 to US$22.33. Share price fell 8.1% to US$13.68 over the past week. 
